TRCT
TLSI icon

Tower Research Capital (TRC)’s TriSalus Life Sciences TLSI Stock Holding History

Tower Research Capital (TRC)’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.6K Buy
11,403
+9,630
+543% +$47.2K ﹤0.01% 2820
2025
Q4 		$12.4K Sell
1,773
-1,240
-41% -$6.94K ﹤0.01% 3487
2025
Q3 		$14K Buy
3,013
+2,915
+2,974% +$13.6K ﹤0.01% 3633
2025
Q2 		$534 Buy
+98
New +$526 ﹤0.01% 5001
2025
Q1 		– Sell
-555
Closed -$2.78K – 5784
2024
Q4 		$2.78K Sell
555
-1,148
-67% -$4.85K ﹤0.01% 4775
2024
Q3 		$7.85K Sell
1,703
-4,217
-71% -$22.3K ﹤0.01% 4011
2024
Q2 		$32.7K Buy
5,920
+4,378
+284% +$37.1K ﹤0.01% 3420
2024
Q1 		$15K Sell
1,542
-431
-22% -$3.98K ﹤0.01% 3263
2023
Q4 		$16.7K Buy
+1,973
New +$10.2K ﹤0.01% 3772
2022
Q1 		– Sell
-1,336
Closed -$13K – 6554
2021
Q4 		$13K Buy
1,336
+643
+93% +$6.39K ﹤0.01% 4205
2021
Q3 		$7K Buy
+693
New +$6.78K ﹤0.01% 4674
2021
Q2 		– Sell
-100
Closed -$1K – 5841
2021
Q1 		$1K Buy
+100
New +$1.01K ﹤0.01% 5219

Other funds holding TLSI

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

Tower Research Capital (TRC)'s TLSI Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its TriSalus Life Sciences (TLSI) stake by 543% in Q1 2026, buying an estimated $47.2K and bringing the position to 11,403 shares worth $45.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2820.

Tower Research Capital (TRC) first reported a position in TLSI in Q1 2021 and has held it in 12 quarters since. 84 funds tracked by Wall St. Rank hold TLSI as of Q1 2026.

  • Tower Research Capital (TRC) held 11,403 shares of TriSalus Life Sciences worth $45.6K as of Q1 2026.
  • Tower Research Capital (TRC) bought 9,630 TriSalus Life Sciences shares in Q1 2026, an estimated $47.2K.
  • TriSalus Life Sciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2820 holding.
  • Tower Research Capital (TRC) first reported a position in TriSalus Life Sciences in Q1 2021 and has held it in 12 quarters since.
  • 84 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.